Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies

Following the clinical success of cancer immunotherapies such as immune checkpoint inhibitors blocking B7/CTLA-4 or PD-1/PD-L1 signaling and ongoing numerous combination therapies in the clinic,3 bispecific antibodies (BsAbs) are now emerging as a growing class of immunotherapies with the potential...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Gihoon, Won, Jonghwa, Lee, Yangsoon, Moon, Dain, Park, Yunji, Lee, Sang Hoon, Lee, Seung-Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310217/
https://www.ncbi.nlm.nih.gov/pubmed/34358141
http://dx.doi.org/10.3390/vaccines9070724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310217/
https://www.ncbi.nlm.nih.gov/pubmed/34358141
http://dx.doi.org/10.3390/vaccines9070724

Ejemplares similares